AN2 Therapeutics, Inc. (ANTX)

Insider Trading Filed: 2026-04-10

Key Insights

The reporting person, Kabeer Aziz, is a director of AN2 Therapeutics, Inc. (ANTX) and holds both direct and indirect beneficial ownership of the company's common stock.
Aziz acquired 3,775 shares of ANTX common stock on 2026-04-10 as part of the company's non-employee director compensation policy, with the shares vesting immediately.
In addition to Aziz's direct ownership, he may be deemed to have shared voting and dispositive power over a significant amount of ANTX shares held indirectly through two investment funds, Adjuvant Global Health Technology Fund, L.P. and Adjuvant Global Health Technology Fund DE, L.P.

Insider Trading Filed: 2026-04-10

Key Insights

Gilbert Lynn Marks, a director of AN2 Therapeutics, acquired 3,775 shares of the company's common stock on April 10, 2026, representing a direct ownership increase.
The shares were acquired at no cost, likely as part of the company's non-employee director compensation policy.
This insider purchase suggests that Marks is confident in the company's prospects and aligns his interests with those of shareholders.

Insider Trading Filed: 2026-04-10

Key Insights

Patricia A. Martin, a director of AN2 Therapeutics, Inc. (ANTX), acquired 1,192 shares of the company's common stock on April 10, 2026, under the issuer's non-employee director compensation policy. This suggests ongoing confidence in the company by a board member.
The shares acquired by Patricia A. Martin vested immediately, indicating no restrictions on her ability to hold or trade the shares.
The reported transaction represents a direct ownership interest in the company, providing insight into the director's alignment with shareholder interests.

Current Report Filed: 2026-04-09

Key Insights

AN2 Therapeutics has entered into a new Open Market Sale Agreement with Jefferies LLC, allowing the company to issue and sell up to $80 million in common stock at its discretion.
The company has terminated its previous sales agreement with Cowen and Company, LLC, which had allowed it to sell $20 million in shares.
This new agreement provides AN2 Therapeutics with additional financial flexibility and access to capital markets to fund its operations and development efforts.

Insider Trading Filed: 2026-03-23

Key Insights

The filing indicates that the Chief Operating Officer and Chief Legal Officer, Joshua M. Eizen, has exercised 92,000 stock options at a lower exercise price of $3.91, potentially signaling his confidence in the company's future performance.
Eizen has also had 92,000 stock options with a higher exercise price of $17.88 canceled, suggesting the company is proactively managing its equity compensation structure.
The filing also shows that Eizen has been granted an additional 50,150 stock options with a lower exercise price of $3.91, further aligning his interests with those of the company and its shareholders.

Insider Trading Filed: 2026-03-23

Key Insights

Lucy Day, the Chief Financial Officer of AN2 Therapeutics, Inc. (ANTX), has exercised 221,965 stock options and sold 221,965 shares on 2026-03-19, indicating significant insider selling activity.
The exercise price of the options was repriced from the original price to $3.91 per share, which is the closing price of the company's common stock on the repricing date. This may indicate that the original exercise price was no longer attractive to the executive.
The vesting schedules of the options suggest that the executive has been granted multiple equity awards over time, and the recent exercise and sale activity could be part of a planned diversification of her holdings.

Insider Trading Filed: 2026-03-23

Key Insights

The reporting person, Sanjay Chanda, is the Chief Development Officer of AN2 Therapeutics, Inc. and has received multiple stock option grants.
Chanda exercised 66,000 stock options with an exercise price of $3.91 and simultaneously disposed of 66,000 stock options with an exercise price of $17.28, indicating he may be taking some profits.
Chanda also received additional 57,950 and 41,665 stock options with an exercise price of $3.91, suggesting continued commitment to the company.

Insider Trading Filed: 2026-03-23

Key Insights

The reporting person, Gilbert Lynn Marks, has received a repricing of multiple stock options, indicating potential alignment of incentives with the company's long-term performance.
The option repricing provides the reporting person with a lower exercise price of $3.91, potentially allowing them to benefit from future stock price appreciation.
The option repricing is subject to certain conditions, including a 'Premium End Date' and potential reversal of the repricing if the options are exercised or the reporting person's service is terminated prior to that date.

Insider Trading Filed: 2026-03-23

Key Insights

The reporting person, Kabeer Aziz, who is a director of AN2 Therapeutics, Inc. (ANTX), acquired 20,724 stock options and disposed of 20,724 stock options on March 19, 2026.
The exercise price of the acquired options was repriced from $17.28 to $3.91, potentially signaling a positive view on the company's prospects.
Kabeer Aziz also acquired an additional 23,742 stock options on March 19, 2026, further demonstrating his commitment to the company.

Insider Trading Filed: 2026-03-23

Key Insights

Insider Patricia A. Martin, a director of AN2 Therapeutics, Inc., has acquired additional stock options worth 24,999, 10,362, and 23,742 shares, indicating her continued confidence in the company.
The company has repriced some of Martin's existing stock options to a lower exercise price of $3.91, potentially providing her with more favorable terms and further aligning her interests with shareholders.
The timing of these transactions, occurring in March 2026, suggests that the company and its insiders may have positive long-term expectations for the business.

Insider Trading Filed: 2026-03-23

Key Insights

The reporting person, Margaret M. FitzPatrick, a director of AN2 Therapeutics, Inc. (ANTX), has engaged in multiple transactions involving the company's stock options, including the acquisition of new options and the disposition of existing options.
The reported transactions suggest that FitzPatrick's equity ownership in the company has been relatively stable, with the net change in her beneficial ownership of the company's common stock appearing to be minimal.
The option repricing event, where the exercise price of certain options was reduced to the current market price, may indicate the company's efforts to retain and incentivize its directors during this period.

Insider Trading Filed: 2026-03-23

Key Insights

The reporting person, Stephanie Wong, acquired new stock options and had existing options repriced, indicating potential confidence in the company's future performance.
The repricing of the stock options suggests the company is taking steps to retain key personnel and align their incentives with shareholder interests.
The timing of the transactions, occurring in March 2026, may indicate the reporting person's view of the company's near-term prospects.

Insider Trading Filed: 2026-03-23

Key Insights

The reporting person, Joseph S. Zakrzewski, is a director of AN2 Therapeutics, Inc. and has been granted several stock options that have been repriced.
The stock options were repriced on March 19, 2026, with the exercise price being reduced from higher levels to $3.91 per share, which was the closing price of the company's stock on that date.
The repricing of the stock options may indicate that the company is providing incentives to its directors to retain them and align their interests with those of the shareholders.

Insider Trading Filed: 2026-03-23

Key Insights

Insider Melvin K. Spigelman, who is a director at AN2 Therapeutics, has received a significant number of stock options, including 16,941 options repriced to $3.91 and an additional 10,362 and 23,742 options granted at $3.91 and $3.91, respectively.
The repricing of options to a lower exercise price of $3.91 per share suggests the company may be facing challenges, as insiders are being given incentives to maintain their stake in the company.
The large number of options granted to Spigelman, totaling 50,045 shares, indicates the company is relying heavily on equity-based compensation to retain its key personnel.

Insider Trading Filed: 2026-03-23

Key Insights

Insider Robin Shane Readnour has made significant option grants and repricing, indicating potential confidence in the company's future performance.
The repricing of options to a lower exercise price of $3.91 may suggest the company is seeking to retain and incentivize key personnel.
The large number of option grants (over 40,000) and the upcoming expiration dates (2032 and 2033) indicate a long-term focus on equity-based compensation.

Insider Trading Filed: 2026-03-23

Key Insights

Eric Easom, the CEO of AN2 Therapeutics, Inc. (ANTX), has made significant changes to his stock option holdings, including the repricing of existing options and the acquisition of new options.
Easom has exercised 249,999 stock options with a strike price of $6.596 and acquired 249,999 new options with a strike price of $3.91, suggesting he believes the stock is undervalued.
The company has also granted Easom an additional 225,000 stock options with a strike price of $3.91 and 267,650 options with a strike price of $3.91, further aligning his interests with those of shareholders.

Current Report Filed: 2026-03-20

Key Insights

The company approved a stock option repricing program that reduces the exercise price of all outstanding stock options to $3.91 per share, the closing price on the repricing date. This should provide added incentives to retain and motivate plan participants without significant stock dilution or cash expenditures.
The repricing program includes a 'Premium End Date' where holders must pay the original exercise price if the options are exercised prior to September 19, 2027, a change in control, or the holder's death/disability. This helps align participants' interests with long-term shareholder value creation.
The company's named executive officers hold a significant number of the eligible options, with exercise prices ranging from $6.60 to $17.88 per share. The repricing and retention program may help secure their continued leadership during this critical period.

Current Report Filed: 2026-03-10

Key Insights

AN2 Therapeutics, Inc. has entered into a $40 million private placement with certain investors, providing the company with additional capital to fund its operations.
The company issued 8,245,611 shares of common stock and 5,789,493 pre-funded warrants as part of the private placement, with the warrants exercisable at a price of $0.00001 per share.
The company has agreed to file a resale registration statement with the SEC within 30 days of the closing of the private placement to register the shares issued and the shares underlying the pre-funded warrants.

Current Report Filed: 2026-01-29

Key Insights

AN2 Therapeutics has appointed Sarah Williams as its new Vice President, Controller and Principal Accounting Officer, indicating a change in the company's leadership team.
The company has entered into an Amended and Restated Employment Letter Agreement with Lucy Day, the current Chief Financial Officer and Principal Financial Officer, which includes a reduction in her annual base salary effective April 1, 2026.
The company is undertaking cost-saving efforts, as evidenced by the reduction in Lucy Day's compensation, which could have implications for the company's financial performance and operations.

Insider Trading Filed: 2026-01-14

Key Insights

Kabeer Aziz, a director of AN2 Therapeutics, Inc. (ANTX), acquired 11,560 shares of the company's common stock through a grant in lieu of cash compensation.
Aziz also holds indirect beneficial ownership of over 2.3 million shares of ANTX through his positions at Adjuvant Global Health Technology Fund, L.P. and Adjuvant Global Health Technology Fund DE, L.P.
The acquisition of shares by a director, especially in significant quantities, may indicate management's confidence in the company's prospects and could be seen as a positive signal to investors.

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Key Insights

Important Information